{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:43:05Z","timestamp":1793270585369,"version":"4.5.0"},"reference-count":21,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.2967\/jnumed.123.266211","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:10:15Z","timestamp":1704989415000},"page":"264-269","source":"Crossref","is-referenced-by-count":61,"title":["Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial"],"prefix":"10.2967","volume":"65","author":[{"given":"Etienne","family":"Garin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Chalaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"de Baere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Tacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Palard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"D\u00e9andreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mariano-Goulart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Amaddeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Boudjema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Azhar","family":"Meerun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Campillo-Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"2024020105551726000_65.2.264.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2024020105551726000_65.2.264.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"2024020105551726000_65.2.264.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29691"},{"key":"2024020105551726000_65.2.264.4","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol."},{"key":"2024020105551726000_65.2.264.5","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol."},{"key":"2024020105551726000_65.2.264.6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol."},{"key":"2024020105551726000_65.2.264.7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Selective internal radiation therapy (SIRT) using personalised dosimetry for locally advanced hepatocellular carcinoma (HCC) patients: a multicentre randomised phase 2 study (DOSISPHERE-01 trial)","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2024020105551726000_65.2.264.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.094235"},{"key":"2024020105551726000_65.2.264.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"2024020105551726000_65.2.264.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"2024020105551726000_65.2.264.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.145177"},{"key":"2024020105551726000_65.2.264.12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J Hepatol."},{"key":"2024020105551726000_65.2.264.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27057"},{"key":"2024020105551726000_65.2.264.14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants","volume":"48","author":"Gabr","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024020105551726000_65.2.264.15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology."},{"key":"2024020105551726000_65.2.264.16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.21037\/hbsn-22-184","article-title":"Large, multifocal or portal vein-invading HCCs downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery","volume":"1","author":"Meerun","year":"2023","journal-title":"Hepatobiliary Surg Nutr."},{"key":"2024020105551726000_65.2.264.17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0454-0"},{"key":"2024020105551726000_65.2.264.18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00259-017-3845-7","article-title":"Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma","volume":"45","author":"Palard","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024020105551726000_65.2.264.19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315485"},{"key":"2024020105551726000_65.2.264.20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12885-020-6613-1","article-title":"Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy","volume":"20","author":"Craciun","year":"2020","journal-title":"BMC Cancer."},{"key":"2024020105551726000_65.2.264.21","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1002\/cam4.4090","article-title":"Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial","volume":"10","author":"Salem","year":"2021","journal-title":"Cancer Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:56:59Z","timestamp":1706795819000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.2967\/jnumed.123.266211"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266211","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}